Corporate News
Bayer named best pharmaceutical and chemical company in Brazil
Sao Paulo / Leverkusen, November 13, 2008 – Bayer is recognized as Brazil’s best chemical and pharmaceutical company. This was the result of a survey of 12,000 consumers conducted by Época Negocios... more
Professor Berschauer: “Enabling a second green revolution in Asia with new, high-yielding rice varieties”
Rice seed production in Asia to be expanded substantially by 2017 more
Bayer’s Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome
Phase II Data Presented as Late-Breaker at American Heart Association Meeting / Phase III Study to be Initiated in December 2008 more
“Environmental Envoys” from 18 countries visit Bayer
Project part of partnership between the United Nations Environment Programme (UNEP) and Bayer more
Interim report for the third quarter of 2008: Bayer optimistic about future business trend
Sales rise by 2.0 percent to EUR 7,948 million (Q3 2007: EUR 7,793 million) / HealthCare and CropScience improve earning power / MaterialScience earnings significantly lower / Group EBITDA before... more
EUR 150,000 for scholarships and education of teachers
Funding for ambitious projects in ten countries / Focus on natural sciences and medicine more
Bayer significantly strengthens its presence in China
Startup of 350,000 tons/year MDI train / Groundbreaking for 250,000 tons/year TDI plant / Isocyanate production also to be expanded in Europe in the medium term more
First estradiol-based oral contraceptive Qlaira® cleared for market launch in Europe
A new oral contraceptive providing the same estrogen produced by the female body more
Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU
Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care more
Bayer starts new research cooperation in Asia
Research collaboration with National University of Singapore signed / Further collaborations planned / Overall investment volume of 10 million Euro more
Squeeze-out entered in the Commercial Register
Squeeze-out of minority stockholders takes effect / Cash compensation of EUR 98.98 per share will be paid more
“We need a second green revolution”
The need to exploit all technological options for increasing yields more
Five year data confirm that early treatment with Betaferon® at first sign of disease can delay progression to MS
BENEFIT is first and only prospectively planned study to show long lasting benefit of early treatment more
Bayer MaterialScience LLC declares force majeure in the USA
Leverkusen/Baytown, September 19, 2008 – Bayer MaterialScience LLC, the North American subsidiary of Bayer MaterialScience AG, has declared force majeure for a large part of its production in... more
Bayer HealthCare acquires German DIREVO Biotech AG
A recognized leader in protein engineering / Expanding technological know-how in biologicals / Strengthening Bayer HealthCare’s commitment to develop innovative biologicals more
Bayer’s Xarelto® Approved in Canada
First approval for Bayer’s new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral,... more
The Search is on for the Best Pictures on the Subject of Climate Change
Winners are honored at an international event; attractive prizes to be won / More than 190,000 children from over 100 countries have submitted pictures since 1991 more
New low-dose oral contraceptive YAZ® launched in Europe
24/4 dosing regimen has shown to reduce hormone fluctuations more
Bayer CropScience plans investment of EUR 3.4 billion in research and development through 2012
Expansion of R&D program will strengthen basis for future growth / Achievement of target EBITDA margin of around 25 percent already expected in 2008 / Sales target of EUR 2 billion with new active... more
Otto Bayer Medals awarded for outstanding research
Three research teams from Bayer commended for innovations in healthcare, nutrition and high-tech materials / Bayer has the highest level of research and development spending in the German chemical... more
Sustainable help for earthquake-stricken college in Sichuan
Donation of 20 classrooms, 50 homes and a mobile clinic more
Bayer Submits Recombinant Human Thrombin for European Approval
Recothrom® would be the first recombinant human thrombin for use as a topical aid to surgical hemostasis in Europe more
Thiencarbazone-methyl registered in first market
Annual sales potential of more than EUR 100 million for new corn herbicide more
Bayer MaterialScience starts construction of a world-scale TDI plant in Shanghai
Annual capacity of 250,000 metric tons approved / Capacity can be increased to 300,000 metric tons per year / Start-up planned for 2010 more
Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration
Study patients, on average, received only two additional doses following a 12-week fixed dosing period more
Bayer’s Annual Report Receives International Praise
New York, August 12, 2008 – Praise all around for Bayer’s Annual Report 2007: It received gold, silver, bronze and honors twice each in the recently concluded Annual Report Competition (ARC). More... more
Bayer appoints Greg Babe as new CEO for U.S. Organisation
Predecessor Dr. Attila Molnar to retire more
Bayer continues its success
Sales up 3.6 percent to EUR 8,511 million / EBITDA before special items increases by 5.0 percent to EUR 1,896 million / EBIT before special items improves by 5.3 percent to EUR 1,248 million /... more
Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.
Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues... more
Nexavar Approved for Treatment of Liver Cancer in China
Nexavar is First Approved Systemic Therapy to Treat the Disease more
Bayer’s Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU
Final approval from the European Commission expected within the next few months more
Andreas Fibig named new Chairman of the Board of Management of Bayer Schering Pharma
Dr. Bernd Metzner to become new Board member of Bayer’s pharmaceuticals subsidiary / Arthur Higgins and Werner Baumann to refocus on their leadership roles in the Bayer HealthCare subgroup following... more
Tembotrione from Bayer CropScience approved in Brazil
Launch of Soberan® planned for 2008 more
Primovist® approved in the U.S. for the Detection and Characterization of Liver Lesions
Berlin, July 8, 2008 – The U.S. Food and Drug Administration (FDA) has approved Bayer Schering Pharma’s magnetic resonance imaging (MRI) contrast agent Primovist® (gadoxetate disodium) for the... more
Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology
Significantly Strengthens Consumer Care Division’s Business in High Growth Chinese OTC Market more
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen’s novel biotechnology research platform more
Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United States
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer’s Women’s Healthcare Business Unit expected more
Bayer receives Environmental Award from the Federation of German Industries
Energy-efficient process recycles chlorine from hydrochloric acid / Industrial application in Germany and China / Bayer Management Board member Dr. Plischke: “Increase in energy efficiency brings... more
Bayer plans to invest EUR 100 million in Brazil
Wenning: “Brazil is our biggest market in Latin America” more
Bayer CEO Werner Wenning receives prestigious McCloy Award
Former German Foreign Minister Hans-Dietrich Genscher presents the honor in New York more
Bayer will use tobacco plants to produce medicines
First development candidate from the new plant for cancer indication non-Hodgkin’s lymphoma – Clinical phase I could start in 2009 / Bayer has invested over EUR 10 million in Halle since 2006 more
Bayer Climate Program makes great advances
Climate protection projects rigorously implemented / Commitment to global health care provision / EUR 45 million spent annually to support 300 social projects worldwide / EUR 500,000 per year alone... more
Bayer HealthCare successfully completes acquisition of Sagmel, Inc.’s OTC Business
Bayer Consumer Care’s Presence in Eastern Europe Significantly Strengthened more
Bayer increases aid to disaster victims in China and Burma
Cash and material donations now stand at more than EUR 1.4 million more
Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice-Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates / RECORD4 Confirms Results of RECORD1, 2... more
Nexavar Significantly Extends Overall Survival in Liver Cancer
Trial Results Confirm Efficacy for Population Most Affected by the Disease more
Bayer to Help Victims of Natural Disasters in China and Burma
Goods and Funds Donation in the Amount of 350,000 Euros more
Bayer lays the foundation for its zero-emission building in India
The “EcoCommercial Building” concept saves 70 percent of electrical energy / Chairman of the Bayer Board of Management Werner Wenning: “A milestone in the Bayer Climate Program” / More buildings to... more
Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
International study to evaluate efficacy and safety in treating a leading cause of blindness more
Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe
Berlin, May 6, 2008 – Bayer Schering Pharma’s new low-dose oral contraceptive YAZ® has been approved in the EU.YAZ® will be the first oral contraceptive on the European market containing the unique... more
“2007 was Bayer’s most successful year to date”
Previous year’s record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded more
Bayer off to an excellent start in 2008
Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for... more
Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®
Leverkusen, April 21, 2008 – Bayer confirmed that Bayer Schering Pharma AG and Bayer HealthCare Pharmaceuticals Inc. filed a patent infringement lawsuit in U.S. Federal Court in the Southern District... more
Bayer donates €250,000 for patients with hemophilia and provides nearly 1 million international units of Kogenate®
World Hemophilia Day on April 17th more
Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical
Merger to Be Completed Shortly more
Bayer appeals invalidity ruling on its Yasmin® Patent
Appeal will be heard by the Federal Circuit more
Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
Leverkusen, Germany, / Minneapolis, MN, USA – Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA and Possis Medical, Inc., Minneapolis, MN, (Nasdaq: POSS), announced today that they have entered... more
Nexavar® Approved for the Treatment of Kidney Cancer in Japan
First approved oral targeted therapy for metastatic RCC in Japan more
Bayer extends product portfolio for liver cancer patients in Japan
Japanese authorities grant priority review status for Nexavar® in liver cancer / Launch of liver-specific contrast agent Primovist® in Japan more
Bayer establishes US special access program for Leukine® while replacing current liquid formulation
Leukine lyophilized formulation temporarily reserved for patients with Acute Myelogenous Leukemia (AML) and those experiencing bone marrow transplantation graft failure or engraftment delay / Bayer... more
US Food and Drug Administration Approves RECOTHROM™
Leverkusen – Bayer HealthCare announced today that its partner, ZymoGenetics Inc., received US Food and Drug Administration (FDA) approval of RECOTHROM™ Thrombin, topical (recombinant) for use as a... more
Archer Daniels Midland Company, Bayer CropScience and Daimler to cooperate in Jatropha biodiesel project
A new high-potential biofuel crop more
Expanded Labeling for MabCampath® in Europe
B-cell chronic lymphocytic leukemia (B-CLL): more